ArticleMediterranean journal of rheumatology2026
Elevated Serum Follistatin-Like Protein 1 Levels Correlate with Disease Activity and Severity in Behçet's Disease: A Case-Control Study.
Article in Mediterranean journal of rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Behçet's disease (BD) is chronic multisystem inflammatory condition with wide spectrum of clinical manifestations, lacking specific laboratory biomarkers for diagnosis or monitoring. Follistatin-like protein 1 (FSTL1), having dual roles in inflammation, remains largely unexplored in BD. The present study aimed to evaluate FSTL1 levels in the serum of BD patients and investigate their association with disease activity and severity. Methods: This prospective, hospital-based case-control study included 40 BD patients, the control group consisted of 40 healthy individuals age and sex matched with the patients. FSTL1 concentrations were measured using a double-antibody sandwich ELISA. The disease activity and cumulative disease related damage were assessed using the Behçet's Disease Current Activity Form (BDCAF), and the Behçet's Syndrome Overall Damage Index (BODI). Results: The median serum FSTL1 concentrations were significantly elevated in BD patients in comparison to controls :4.05 (1.9 - 9.1), 3.55 (2.2 - 4.8) ng/ml; p = 0.024, r (rank-biserial correlation) = 0.036 represent very small effect size. FSTL1 levels also showed moderate positive correlations with both BDCAF (r = 0.397) and BODI (r = 0.391) scores, suggesting that higher FSTL1 levels reflect increased inflammatory activity and tissue involvement. Conclusion: Our study demonstrates an elevation in serum FSTL1 levels in BD and positively correlate with disease BD activity and cumulative damage. FSTL1 may reflect inflammatory burden in BD, but further validation is needed to establish causality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.